Patents by Inventor George E. Mark

George E. Mark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for reducing the immunogenicity of antibody variable domains
    Publication number: 20040253645
    Abstract: A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.
    Type: Application
    Filed: July 2, 2004
    Publication date: December 16, 2004
    Inventors: Bruce L. Daugherty, George E. Mark, Eduardo A. Padlan
  • Method for reducing the immunogenicity of antibody variable domains
    Patent number: 6797492
    Abstract: A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: September 28, 2004
    Assignees: Merck & Co., Inc., United States of America
    Inventors: Bruce L. Daugherty, George E. Mark, III, Eduardo A. Padlan
  • Homologous recombination antibody expression system for murine cells
    Patent number: 6750041
    Abstract: A specific locus in the genome of a murine host cell is identified which causes high levels of recombinant gene expression following stable integration, via homologous recombination, of the recombinant gene into the specific chromosomal locus. The selection of a favorable genome locus for the insertion and expression of a recombinant gene is disclosed, as are DNA vectors and host cells.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: June 15, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Gregory Franklin Hollis, George E. Mark
  • Homologous recombination antibody expression system for murine cells
    Patent number: 6743622
    Abstract: A specific locus in the genome of a murine host cell is identified which causes high levels of recombinant gene expression following stable integration, via homologous recombination, of the recombinant gene into the specific chromosomal locus. The selection of a favorable genome locus for the insertion and expression of a recombinant gene is disclosed, as are DNA vectors and host cells.
    Type: Grant
    Filed: November 7, 1996
    Date of Patent: June 1, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Gregory Franklin Hollis, George E. Mark
  • HOMOLOGOUS RECOMBINATION ANTIBODY EXPRESSIONS SYSTEM FOR MURINE CELLS
    Publication number: 20030124648
    Abstract: A specific locus in the genome of a murine host cell is identified which causes high levels of recombinant gene expression following stable integration, via homologous recombination, of the recombinant gene into the specific chromosomal locus. The selection of a favorable genome locus for the insertion and expression of a recombinant gene is disclosed, as are DNA vectors and host cells.
    Type: Application
    Filed: November 7, 1996
    Publication date: July 3, 2003
    Inventors: GREGORY F. HOLLIS, GEORGE E. MARK
  • HOMOLOGOUS RECOMBINATION ANTIBODY EXPRESSION SYSTEM FOR MURINE CELLS
    Publication number: 20030082673
    Abstract: A specific locus in the genome of a murine host cell is identified which causes high levels of recombinant gene expression following stable integration, via homologous recombination, of the recombinant gene into the specific chromosomal locus. The selection of a favorable genome locus for the insertion and expression of a recombinant gene is disclosed, as are DNA vectors and host cells.
    Type: Application
    Filed: November 14, 1997
    Publication date: May 1, 2003
    Inventors: GREGORY F. HOLLIS, GEORGE E. MARK
  • Method for reducing the immunogenicity of antibody variable domains
    Publication number: 20020034765
    Abstract: A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.
    Type: Application
    Filed: March 16, 2001
    Publication date: March 21, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Bruce L. Daugherty, George E. Mark, Eduardo A. Padlan
  • Formulations of recombinant papillomavirus vaccines
    Patent number: 6280740
    Abstract: Vaccine formulations comprising recombinant early (E) and late (L) proteins of papillomavirus and oxidized mannan as well as methods of making and using the formulations are provided.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: August 28, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Sunil K. Gupta, George E. Mark, III
  • Vampire bat salivary plasminogen activators
    Patent number: 5830849
    Abstract: Purified plasminogen activator proteins obtained or derived from the vampire bat Desmodus rotundus saliva and salivary glands, methods for purifying the proteins, DNA sequences encoding these proteins, means for producing them using recombinant DNA technology, pharmaceutical compositions comprising these proteins and methods of treatment utilizing these proteins are provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 3, 1998
    Assignee: Schering Aktiengesellschaft
    Inventors: Richard A. F. Dixon, Stephen J. Gardell, Le Thi Duong, Paul A. Friedman, John W. Jacobs, George E. Mark, Bruce L. Daugherty
  • Synthetic HPV11 virus-like particles
    Patent number: 5795754
    Abstract: The present invention is a series of synthetic virus-like particles useful in the characterization of human papillomavirus infection and assays employing the synthetic virus-like particles.
    Type: Grant
    Filed: July 19, 1996
    Date of Patent: August 18, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Steven Ludmerer, Gregory F. Hollis, Diana Benincasa, George E. Mark, III
  • Synthetic HPV11 virus-like particles
    Patent number: 5738853
    Abstract: The present invention is a series of synthetic virus-like particles useful in the characterization of human papillomavirus infection and assays employing the synthetic virus-like particles. The synthetic virus-like particles are generated from constructs designated as HPV6:4; HPV6:5; HPV6:2; HPV6:4.DELTA.132; and HPV6:4,S131G.
    Type: Grant
    Filed: October 24, 1996
    Date of Patent: April 14, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Steven Ludmerer, George E. Mark, III, Diana Benincasa
  • Antistasin derived anticoagulant protein
    Patent number: 5189019
    Abstract: A protein having a molecular weight of about 6,000 daltons which is biologically active in the inhibition of Factor Xa during the blood coagulation cascade, a method for producing the protein, methods for inhibiting blood coagulation using the protein, and suitable pharmaceutical compositions.
    Type: Grant
    Filed: April 23, 1990
    Date of Patent: February 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Linda O. Palladino, Melvin Silberklang, Jwu-Sheng Tung, Simon W. Law, George E. Mark